{"nctId":"NCT03695237","briefTitle":"A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)","startDateStruct":{"date":"2018-10-24","type":"ACTUAL"},"conditions":["Central Precocious Puberty (CPP)"],"count":45,"armGroups":[{"label":"Leuprolide Acetate (LA)","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprolide Acetate (LA)"]}],"interventions":[{"name":"Leuprolide Acetate (LA)","otherNames":["Lupron Depot"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children with CPP who are naïve to treatment with a gonadotropin-releasing hormone agonist (GnRHa) (females 2 - 8 years of age, or males 2 - 9 years of age) or who have been on standard GnRHa therapy for at least 6 months (females 2 - 10 years of age, or males 2 - 11 years of age).\n* No history of clinically significant medical conditions or any other reason that the investigator determines would make the participant an unsuitable candidate to receive study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"11 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24","description":"Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg.\n\nPeak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test.\n\nSuppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"81.5","spread":null},{"groupId":"OG002","value":"86.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Suppression of Peak GnRHa-stimulated LH to Less Than 4 mlU/mL at Weeks 12, 20, 44, and 48","description":"Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg.\n\nPeak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test.\n\nSuppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"86.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.4","spread":null},{"groupId":"OG001","value":"85.2","spread":null},{"groupId":"OG002","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"88.9","spread":null},{"groupId":"OG002","value":"88.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"92.6","spread":null},{"groupId":"OG002","value":"88.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Female Participants With Suppression of Basal Estradiol to < 20 pg/mL at Weeks 12, 20, 24, 44, and 48","description":"Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration at Weeks 24 and 48).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"95.5","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"95.7","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"95.2","spread":null},{"groupId":"OG002","value":"97.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Male Participants With Suppression of Basal Testosterone to < 30 ng/dL at Weeks 12, 20, 24, 44, and 48","description":"Testosterone concentrations were measured from blood samples taken at each study visit prior to stimulation testing (and prior to study drug administration for Weeks 24 and 48).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Suppression of the Physical Signs of Puberty","description":"Breast development in females and testicular volume or genital development in males was assessed using modified Tanner staging, on a scale from Stage 1 (prepubertal) to Stage 5 (adult characteristics).\n\nFemales: Suppression is defined as regression or no progression of breast development according to modified Tanner staging.\n\nMales: Suppression is defined as regression or no progression in testicular volume and genital staging according to modified Tanner staging.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"91.7","spread":null},{"groupId":"OG002","value":"92.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"91.7","spread":null},{"groupId":"OG002","value":"90.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.8","spread":null},{"groupId":"OG001","value":"95.7","spread":null},{"groupId":"OG002","value":"94.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"94.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.7","spread":null},{"groupId":"OG001","value":"89.5","spread":null},{"groupId":"OG002","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"86.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"75.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"66.7","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Change From Baseline in Incremental Growth Rate","description":"Growth rate (height in centimeter/year) was calculated both prior to treatment in the study and during the study. For Baseline calculation a historical measurement of height at least 6 months prior to Screening and the Screening value was used.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"9.99"},{"groupId":"OG001","value":"-0.9","spread":"10.52"},{"groupId":"OG002","value":"-0.8","spread":"10.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"4.09"},{"groupId":"OG001","value":"-2.9","spread":"5.42"},{"groupId":"OG002","value":"-2.0","spread":"5.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.61"},{"groupId":"OG001","value":"-3.8","spread":"4.69"},{"groupId":"OG002","value":"-2.5","spread":"4.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.81"},{"groupId":"OG001","value":"-3.7","spread":"4.28"},{"groupId":"OG002","value":"-2.4","spread":"4.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"2.48"},{"groupId":"OG001","value":"-4.1","spread":"3.77"},{"groupId":"OG002","value":"-2.6","spread":"3.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"2.67"},{"groupId":"OG001","value":"-3.5","spread":"4.71"},{"groupId":"OG002","value":"-2.3","spread":"4.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"2.09"},{"groupId":"OG001","value":"-4.3","spread":"3.53"},{"groupId":"OG002","value":"-2.8","spread":"3.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"2.29"},{"groupId":"OG001","value":"-4.9","spread":"3.43"},{"groupId":"OG002","value":"-3.2","spread":"3.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.96"},{"groupId":"OG001","value":"-5.6","spread":"3.27"},{"groupId":"OG002","value":"-3.9","spread":"3.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.63"},{"groupId":"OG001","value":"-5.3","spread":"2.76"},{"groupId":"OG002","value":"-4.0","spread":"3.19"}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Ratio of Change From Baseline in Bone Age to Change From Baseline in Chronological Age","description":"Bone age was assessed from radiographs of the hand and wrist by a central imaging vendor using the BoneXpert automated system.\n\nA ratio less than 1 indicates less advancement of bone age compared to chronological age.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.80"},{"groupId":"OG001","value":"0.7","spread":"0.56"},{"groupId":"OG002","value":"0.6","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.36"},{"groupId":"OG001","value":"0.6","spread":"0.41"},{"groupId":"OG002","value":"0.5","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.31"},{"groupId":"OG001","value":"0.6","spread":"0.38"},{"groupId":"OG002","value":"0.6","spread":"0.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.32"},{"groupId":"OG001","value":"0.7","spread":"0.28"},{"groupId":"OG002","value":"0.6","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.28"},{"groupId":"OG001","value":"0.6","spread":"0.34"},{"groupId":"OG002","value":"0.6","spread":"0.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.26"},{"groupId":"OG001","value":"0.6","spread":"0.24"},{"groupId":"OG002","value":"0.6","spread":"0.24"}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Maintenance of Suppression of GnRHa-stimulated LH (< 4 mlU/mL)","description":"Suppression of GnRHa-stimulated luteinizing hormone (LH) was measured using a peak GnRHa stimulation test, performed using subcutaneous injection with an aqueous formulation of leuprolide acetate at 20 µg/kg.\n\nPeak stimulated LH was calculated by taking the maximum LH concentrations measured from blood samples taken at 30 or 60 min following the GnRHa stimulation test.\n\nSuppression of GnRHa-stimulated luteinizing hormone is defined as peak stimulated LH less than 4 mIU/mL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"93.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.3","spread":null},{"groupId":"OG001","value":"95.7","spread":null},{"groupId":"OG002","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Female Participants With Maintenance of Suppression of Basal Estradiol to < 20 pg/mL","description":"Estradiol concentrations were measured from blood samples taken at each study visit prior to stimulation testing.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Male Participants With Maintenance of Suppression of Basal Testosterone to < 30 ng/dL","description":"Male participants with maintenance of suppression of testosterone to \\< 30 ng/dL are assessed","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["INJECTION SITE PAIN","HEADACHE","INJECTION SITE REACTION","COVID-19","UPPER RESPIRATORY TRACT INFECTION"]}}}